The primary aim of WJD is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. In order to ensure the quality, timeliness, fairness, and transparency of publication, WJD has implemented a variety of measures as follows:

First, authors must prepare their articles according to the appropriate international publication recommendations, including the STROBE Statement, CONSORT 2010 Statement, PRISMA 2009 Checklist, and CARE Checklist – 2016: Information for writing a case report.

Second, articles published in WJD must undergo rigorous cross-international peer review. WJD peer reviewers come from different countries, chosen independently by artificial intelligence technique or our editorial office, and not by the authors, to ensure fairness and integrity of the peer review.

Third, designation of co-first authors and/or co-corresponding authors is not permitted.

Fourth, WJD accepts a manuscript for publication based on its novelty, innovativeness, data accuracy, image reliability, clear language expression, and ethical requirements.

Of note, peer reviewers are advised to complete their peer review within 7 days, providing a comprehensive evaluation of the scientific and linguistic quality of the manuscript.

Fifth, BPG adopts a 7-day publishing management policy. This means that each step of the publishing process, including manuscript preview, peer review, manuscript revision by authors, final acceptance, language editing, and production, and release, must be completed within 7 days.

The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJD as 4.2; IF without journal self cites: 4.1; 5-year IF: 4.5; Journal Citation Indicator: 0.69; Ranking: 51 among 145 journals in endocrinology and metabolism; and Quartile category: Q2.